<DOC>
	<DOCNO>NCT00917839</DOCNO>
	<brief_summary>This study design evaluate neuroprotective effect lamotrigine combination interferon beta 1a weekly intramuscular patient relapsing-remitting multiple sclerosis .</brief_summary>
	<brief_title>The Neuroprotective Effect Lamotrigine Interferon Beta 1a Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<mesh_term>Neuroprotective Agents</mesh_term>
	<criteria>definitive multiple sclerosis accord Mc Donald criterion clinical isolate syndrome accord Mc Donald criterion Expanded Disability Status Scale Score 05 Pretreatment interferon beta 1a ( Avonex ) since least 2 month inclusion relapse within 30 day prior randomisation steroid pulse therapy within 30 day prior randomisation pregnancy poor contraception contraindication lamotrigine depressive symptom drug possible interaction lamotrigine accord instruction leaflet medical relevant condition multiple sclerosis clinically relevant laboratory result contraindication MRI miss informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>neuroprotection</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>brain atrophy</keyword>
	<keyword>mr-spectroscopy</keyword>
</DOC>